Indolent Lymphoma – Research into a Tailored Treatment Pathway

Meet Dr Josh Tobin, Lymphoma Researcher and inaugural Snowdome Foundation Haematology Fellow.

Dr Tobin has a special interest in indolent lymphoma, a type of slow growing non-Hodgkin’s lymphoma. Although incurable, many of those diagnosed will not require treatment but for those who do, some will relapse and experience aggressive disease.

The goal of Dr Tobin’s research is to identify, at diagnosis, patients who are likely to relapse and then offer more tailored treatments from the start. His focus centres around immunotherapy, treatment that uses the body’s own immune system against cancer, ultimately lessening reliance on chemotherapy.

Immunotherapy is described as one of the most exciting breakthroughs in cancer treatment and offers enormous hope for the cancer community.